Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arkansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arkansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arkansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Kamal Patel (NPI 1598747164)

Field	Value
Entity Type	Individual
Organization	Kamal Patel
Address	8901 Carti Way
City	Little Rock
State	AR
ZIP	72205
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	November 18, 2005

Payer Source	Total Paid
Medicare	$5.7M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-only biller: Total Medicare revenue is $5.7M while there is no Medicaid billing on file, so payer mix is highly concentrated on Medicare rather than split across both public payers. The absence of any Medicaid codes on file means in‑state Medicaid exposure is negligible for analyses of this NPI.

Revenue is highly concentrated in three immunotherapy drugs: the precomputed top-3 Medicare codes by revenue account for 63.6% of this provider's total Medicare revenue, driven by J9271 ($1.5M, 28.4%), J9299 ($1.3M, 23.9%), and J9022 ($606.7K, 11.3%). This concentration indicates that a few high-cost oncology agents dominate the revenue profile rather than a broad mix of lower-cost services.

The code mix and volumes indicate an outpatient oncology infusion practice focused on immune checkpoint inhibitors and systemic cancer therapies: high-revenue codes include J9271, J9299, and J9022, and the practice also reports significant chemotherapy administration and infusion procedure activity (96413: 1.6K claims, $137.9K revenue; 96375: 2.4K claims, $26.8K revenue). Together these patterns are consistent with frequent IV administration of cancer biologics and on‑site infusion services rather than a primarily diagnostic or surgical specialty.

On competitive standing, this provider is an outlier nationally for key oncology agents: J9299 ranks #6 of 505 providers nationally (99th percentile; extreme outlier) and J9271 ranks #58 of 1841 (97th percentile; notably above typical national volume), signaling unusually high national volume for nivolumab and elevated volume for pembrolizumab relative to peers. At the same time J9022 is ranked #4 of 39 providers (92th percentile; typical, unremarkable volume), meaning the provider is a top-volume participant for some but not all of the high-cost immunotherapies.

Several service and administration codes are also extreme outliers, showing high intensity of office-based oncology care: 99214 (2K claims, $174.8K revenue) ranks #1236 of 479517 providers (100th percentile; extreme outlier) and 96413 ranks #11 of 7514 providers (100th percentile; extreme outlier), with 96375 also flagged at the 100th percentile. These elevated E/M and infusion administration volumes corroborate a high-throughput ambulatory oncology operation with substantial visit- and infusion-related billing.

The provider’s portfolio includes significant use of supportive agents and biosimilars alongside checkpoint inhibitors, which shapes both clinical services and drug procurement exposure: notable entries include J0897 (14.6K claims, $277K), Q5126 (4.6K claims, $258.2K), Q5115 (4.3K claims, $154.8K), J0885 (22.1K claims, $132.8K) and Q5118 (3.6K claims, $90K). This mix of growth‑factor/ supportive care products and biosimilar monoclonal antibodies suggests integrated management of oncology patients (both tumor‑directed and supportive care) and potential sensitivity to biologic pricing and biosimilar adoption.

The NPI tenure is long-standing: NPI enumerated 2005-11-18 (~21 years ago), indicating an established provider presence in the market that aligns with sustained, high-volume Medicare activity rather than a recent entrant. This duration supports interpretation of the billing profile as reflective of an enduring clinical operation rather than a short-term fluctuation.

From a payer‑management and contract perspective, the heavy reliance on a small set of high-cost oncology drugs (top 3 codes = 63.6% of Medicare revenue) creates both negotiating leverage and concentration risk: shifts in reimbursement, utilization, or clinical guidelines for pembrolizumab, nivolumab, or atezolizumab could materially affect overall revenue. Coupled with the lack of Medicaid billing on file, downstream revenue sensitivity is concentrated in Medicare market dynamics and oncology drug utilization patterns rather than in-state Medicaid policy.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

115 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	35,400	$40	$1.5M
J9299	Injection, nivolumab, 1 mg	55,540	$20	$1.3M
J9022	Injection, atezolizumab, 10 mg	9,480	$60	$606.7K
J0897	Injection, denosumab, 1 mg	14,580	$20	$277K
Q5126	Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg	4,610	$60	$258.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	2,030	$90	$174.8K
J1437	Injection, ferric derisomaltose, 10 mg	9,300	$20	$158.1K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	4,300	$40	$154.8K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	4,420	$40	$154.7K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,590	$90	$137.9K

Showing 1–10 of 115

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 115 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arkansas Distribution

Kamal Patel — 17 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arkansas

Full comparison — all codes billed, vs. state median

115 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	3	40	20,700	$40	$896.3K
J9299	1	30	15,660	$20	$432.9K
J9022	1	10	4,940	$60	$407.4K
Q5126	1	10	3,210	$60	$174.1K
J1569	4	10	2,560	$40	$120.3K
J1437	5	20	6,450	$20	$107.8K
Q5115	2	20	2,800	$30	$95.9K
J0897	11	160	2,580	$20	$89.7K
Q5118	2	10	2,110	$20	$64.3K
J2506	2	10	580	$80	$40.4K

Showing 1–10 of 115

Related Providers

Other providers that share a Tax Identification Number (TIN) with Kamal Patel, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Central Arkansas Radiation Therapy Institute Inc	AR	Hematology & Oncology Physician	$0	$11M
Central Arkansas Radiation Therapy Institute Inc	AR	Radiation Oncology Physician	$6.7M	$3.6M
Ryan Hall	AR	Hematology & Oncology Physician	$4.6M	$0
Balagopalan Nair	AR	Hematology & Oncology Physician	$4.1M	$0
Lawrence Mendelsohn	AR	Hematology & Oncology Physician	$3.4M	$0
Jamie Burton	AR	Hematology & Oncology Physician	$2.8M	$0
Kewen Jauss	AR	Hematology & Oncology Physician	$2.8M	$0
Mariann Harrington	AR	Hematology & Oncology Physician	$2.7M	$0
Appalanaidu Sasapu	AR	Hematology & Oncology Physician	$2.6M	$0
Derek Middleton	AR	Hematology & Oncology Physician	$2.5M	$0

Nearby Providers

Other providers in the same ZIP code as Kamal Patel, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
University Of Arkansas For Medical Sciences	AR	General Acute Care Hospital	$0	$87.2M
University Of Arkansas For Medical Sciences	AR	Internal Medicine Physician	$0	$28.6M
University Of Arkansas For Medical Sciences	AR	Pediatrics Physician	$0	$27.6M
Arkansas Department Of Health Immunizations	AR	Public Health or Welfare Agency	$0	$19.3M
Baptist Health	AR	General Acute Care Hospital	$0	$16.4M
Arkansas Department Of Health Family Planning Clinic	AR	Public Health or Welfare Agency	$0	$15.6M
Pediatrix Medical Group Of Arkansas PA	AR	Neonatal-Perinatal Medicine Physician	$0	$14.6M
Chenal Family Therapy, Plc	AR	Mental Health Counselor	$0	$12.2M
Francis A. Allen School For Exceptional Children, Inc.	AR	Developmentally Disabled Services Day Training Agency	$0	$11.9M
Arkansas Department Of Health Std	AR	Public Health or Welfare Agency	$0	$8.4M

Kamal Patel — Billing Profile & Reimbursement Data

Sign up for Kamal Patel — Billing Profile & Reimbursement Data policy alerts

Kamal Patel — Billing Profile & Reimbursement Data

Sign up for Kamal Patel — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References